NEW YORK (GenomeWeb News) — Agilent Technologies has purchased the chemiluminescence product line from GE Healthcare’s Analytical Instruments segment, Agilent said today.
 
The deal includes intellectual property, sales, marketing, and manufacturing assets.
 
New products Agilent acquired through the deal include sulfur and nitrogen chemiluminescence detectors that Agilent said it will incorporate into its Chemical Analysis Solutions unit.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.